{"pmid":32461612,"title":"Vulnerabilities in coronavirus glycan shields despite extensive glycosylation.","text":["Vulnerabilities in coronavirus glycan shields despite extensive glycosylation.","Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66-87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface.","Nat Commun","Watanabe, Yasunori","Berndsen, Zachary T","Raghwani, Jayna","Seabright, Gemma E","Allen, Joel D","Pybus, Oliver G","McLellan, Jason S","Wilson, Ian A","Bowden, Thomas A","Ward, Andrew B","Crispin, Max","32461612"],"abstract":["Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66-87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface."],"journal":"Nat Commun","authors":["Watanabe, Yasunori","Berndsen, Zachary T","Raghwani, Jayna","Seabright, Gemma E","Allen, Joel D","Pybus, Oliver G","McLellan, Jason S","Wilson, Ian A","Bowden, Thomas A","Ward, Andrew B","Crispin, Max"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461612","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41467-020-16567-0","locations":["glycan"],"e_drugs":["Polysaccharides","Nitrogen"],"topics":["Mechanism"],"weight":1,"_version_":1668079521525399553,"score":9.490897,"similar":[{"pmid":32366695,"pmcid":"PMC7199903","title":"Site-specific glycan analysis of the SARS-CoV-2 spike.","text":["Site-specific glycan analysis of the SARS-CoV-2 spike.","The emergence of the betacoronavirus, SARS-CoV-2, the causative agent of COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.","Science","Watanabe, Yasunori","Allen, Joel D","Wrapp, Daniel","McLellan, Jason S","Crispin, Max","32366695"],"abstract":["The emergence of the betacoronavirus, SARS-CoV-2, the causative agent of COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design."],"journal":"Science","authors":["Watanabe, Yasunori","Allen, Joel D","Wrapp, Daniel","McLellan, Jason S","Crispin, Max"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366695","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1126/science.abb9983","e_drugs":["Polysaccharides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496195100672,"score":540.7457},{"pmid":32363391,"title":"Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.","text":["Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.","The current emergence of the novel coronavirus pandemic caused by SARS-CoV-2 demands the development of new therapeutic strategies to prevent rapid progress of mortalities. The coronavirus spike (S) protein, which facilitates viral attachment, entry and membrane fusion is heavily glycosylated and plays a critical role in the elicitation of the host immune response. The spike protein is comprised of two protein subunits (S1 and S2), which together possess 22 potential N-glycosylation sites. Herein, we report the glycosylation mapping on spike protein subunits S1 and S2 expressed on human cells through high resolution mass spectrometry. We have characterized the quantitative N-glycosylation profile on spike protein and interestingly, observed unexpected O-glycosylation modifications on the receptor binding domain (RBD) of spike protein subunit S1. Even though O-glycosylation has been predicted on the spike protein of SARS-CoV-2, this is the first report of experimental data for both the site of O-glycosylation and identity of the O-glycans attached on the subunit S1. Our data on the N- and O- glycosylation is strengthened by extensive manual interpretation of each glycopeptide spectra in addition to using bioinformatics tools to confirm the complexity of glycosylation in the spike protein. The elucidation of the glycan repertoire on the spike protein provides insights into the viral binding studies and more importantly, propels research towards the development of a suitable vaccine candidate.","Glycobiology","Shajahan, Asif","Supekar, Nitin T","Gleinich, Anne S","Azadi, Parastoo","32363391"],"abstract":["The current emergence of the novel coronavirus pandemic caused by SARS-CoV-2 demands the development of new therapeutic strategies to prevent rapid progress of mortalities. The coronavirus spike (S) protein, which facilitates viral attachment, entry and membrane fusion is heavily glycosylated and plays a critical role in the elicitation of the host immune response. The spike protein is comprised of two protein subunits (S1 and S2), which together possess 22 potential N-glycosylation sites. Herein, we report the glycosylation mapping on spike protein subunits S1 and S2 expressed on human cells through high resolution mass spectrometry. We have characterized the quantitative N-glycosylation profile on spike protein and interestingly, observed unexpected O-glycosylation modifications on the receptor binding domain (RBD) of spike protein subunit S1. Even though O-glycosylation has been predicted on the spike protein of SARS-CoV-2, this is the first report of experimental data for both the site of O-glycosylation and identity of the O-glycans attached on the subunit S1. Our data on the N- and O- glycosylation is strengthened by extensive manual interpretation of each glycopeptide spectra in addition to using bioinformatics tools to confirm the complexity of glycosylation in the spike protein. The elucidation of the glycan repertoire on the spike protein provides insights into the viral binding studies and more importantly, propels research towards the development of a suitable vaccine candidate."],"journal":"Glycobiology","authors":["Shajahan, Asif","Supekar, Nitin T","Gleinich, Anne S","Azadi, Parastoo"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363391","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1093/glycob/cwaa042","keywords":["covid-19","coronavirus vaccine","s1 s2 glycosylation","sars-cov-2 glycosylation","spike protein"],"e_drugs":["Nitrogen","Polysaccharides","Glycopeptides"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138496068222977,"score":489.24268},{"pmid":32206694,"pmcid":"PMC7085496","title":"Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).","text":["Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).","The emergence of 2019 novel coronavirus (2019-nCoV) is of global concern and might have emerged from RNA recombination among existing coronaviruses. CoV spike (S) protein which is crucial for receptor binding, membrane fusion via conformational changes, internalization of the virus, host tissue tropism and comprises crucial targets for vaccine development, remain largely uncharacterized. Therefore, the present study has been planned to determine the sequence variation, structural and antigenic divergence of S glycoprotein which may be helpful for the management of 2019-nCoV infection. The sequences of spike glycoprotein of 2019-nCoV and SARS coronavirus (SARS-CoV) were used for the comparison. The sequence variations were determined using EMBOSS Needle pairwise sequence alignment tools. The variation in glycosylation sites was predicted by NetNGlyc 1.0 and validated by N-GlyDE server. Antigenicity was predicted by NetCTL 1.2 and validated by IEDB Analysis Resource server. The structural divergence was determined by using SuperPose Version 1.0 based on cryo-EM structure of the SARS coronavirus spike glycoprotein. Our data suggests that 2019-nCoV is newly spilled coronavirus into humans in China is closely related to SARS-CoV, which has only 12.8% of difference with SARS-CoV in S protein and has 83.9% similarity in minimal receptor-binding domain with SARS-CoV. Addition of a novel glycosylation sites were observed in 2019-nCoV. In addition, antigenic analysis proposes that great antigenic differences exist between both the viral strains, but some of the epitopes were found to be similar between both the S proteins. In spite of the variation in S protein amino acid composition, we found no significant difference in their structures. Collectively, for the first time our results exhibit the emergence of human 2019-nCoV is closely related to predecessor SARS-CoV and provide the evidence that 2019-nCoV uses various novel glycosylation sites as SARS-CoV and may have a potential to become pandemic owing its antigenic discrepancy. Further, demonstration of novel Cytotoxic T lymphocyte epitopes may impart opportunities for the development of peptide based vaccine for the prevention of 2019-nCoV.","Virusdisease","Kumar, Swatantra","Maurya, Vimal K","Prasad, Anil K","Bhatt, Madan L B","Saxena, Shailendra K","32206694"],"abstract":["The emergence of 2019 novel coronavirus (2019-nCoV) is of global concern and might have emerged from RNA recombination among existing coronaviruses. CoV spike (S) protein which is crucial for receptor binding, membrane fusion via conformational changes, internalization of the virus, host tissue tropism and comprises crucial targets for vaccine development, remain largely uncharacterized. Therefore, the present study has been planned to determine the sequence variation, structural and antigenic divergence of S glycoprotein which may be helpful for the management of 2019-nCoV infection. The sequences of spike glycoprotein of 2019-nCoV and SARS coronavirus (SARS-CoV) were used for the comparison. The sequence variations were determined using EMBOSS Needle pairwise sequence alignment tools. The variation in glycosylation sites was predicted by NetNGlyc 1.0 and validated by N-GlyDE server. Antigenicity was predicted by NetCTL 1.2 and validated by IEDB Analysis Resource server. The structural divergence was determined by using SuperPose Version 1.0 based on cryo-EM structure of the SARS coronavirus spike glycoprotein. Our data suggests that 2019-nCoV is newly spilled coronavirus into humans in China is closely related to SARS-CoV, which has only 12.8% of difference with SARS-CoV in S protein and has 83.9% similarity in minimal receptor-binding domain with SARS-CoV. Addition of a novel glycosylation sites were observed in 2019-nCoV. In addition, antigenic analysis proposes that great antigenic differences exist between both the viral strains, but some of the epitopes were found to be similar between both the S proteins. In spite of the variation in S protein amino acid composition, we found no significant difference in their structures. Collectively, for the first time our results exhibit the emergence of human 2019-nCoV is closely related to predecessor SARS-CoV and provide the evidence that 2019-nCoV uses various novel glycosylation sites as SARS-CoV and may have a potential to become pandemic owing its antigenic discrepancy. Further, demonstration of novel Cytotoxic T lymphocyte epitopes may impart opportunities for the development of peptide based vaccine for the prevention of 2019-nCoV."],"journal":"Virusdisease","authors":["Kumar, Swatantra","Maurya, Vimal K","Prasad, Anil K","Bhatt, Madan L B","Saxena, Shailendra K"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32206694","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1007/s13337-020-00571-5","keywords":["2019-ncov","antigenicity","covid-19","coronavirus","glycosylation","s glycoprotein","sars-cov","structural divergence"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490145865728,"score":370.07413},{"pmid":32178593,"pmcid":"PMC7103712","title":"Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26.","text":["Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26.","The recent outbreak of pneumonia-causing COVID-19 in China is an urgent global public health issue with an increase in mortality and morbidity. Here we report our modelled homo-trimer structure of COVID-19 spike glycoprotein in both closed (ligand-free) and open (ligand-bound) conformation, which is involved in host cell adhesion. We also predict the unique N- and O-linked glycosylation sites of spike glycoprotein that distinguish it from the SARS and underlines shielding and camouflage of COVID-19 from the host the defence system. Furthermore, our study also highlights the key finding that the S1 domain of COVID-19 spike glycoprotein potentially interacts with the human CD26, a key immunoregulatory factor for hijacking and virulence. These findings accentuate the unique features of COVID-19 and assist in the development of new therapeutics.","Emerg Microbes Infect","Vankadari, Naveen","Wilce, Jacqueline A","32178593"],"abstract":["The recent outbreak of pneumonia-causing COVID-19 in China is an urgent global public health issue with an increase in mortality and morbidity. Here we report our modelled homo-trimer structure of COVID-19 spike glycoprotein in both closed (ligand-free) and open (ligand-bound) conformation, which is involved in host cell adhesion. We also predict the unique N- and O-linked glycosylation sites of spike glycoprotein that distinguish it from the SARS and underlines shielding and camouflage of COVID-19 from the host the defence system. Furthermore, our study also highlights the key finding that the S1 domain of COVID-19 spike glycoprotein potentially interacts with the human CD26, a key immunoregulatory factor for hijacking and virulence. These findings accentuate the unique features of COVID-19 and assist in the development of new therapeutics."],"journal":"Emerg Microbes Infect","authors":["Vankadari, Naveen","Wilce, Jacqueline A"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32178593","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1739565","keywords":["cd26","coronavirus","docking","glycosylation","spike glycoprotein"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Nitrogen","Polysaccharides"],"topics":["Mechanism"],"weight":1,"_version_":1666138490591510528,"score":313.68964},{"pmid":32422645,"title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","text":["Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.","Nature","Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide","32422645"],"abstract":["SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease."],"journal":"Nature","authors":["Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422645","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2349-y","e_drugs":["Polysaccharides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896791912448,"score":259.40952}]}